Global Tumor Lysis Syndrome Market
Global Tumor Lysis Syndrome Market

Tumor Lysis Syndrome Comprehensive Study by Treatment (Medications (allopurinol, rasburicase, sodium bicarbonate or acetazolamide, oral kinase inhibitors and B-cell lymphoma-2 protein inhibitors), Kidney Dialysis), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online, Others), End-user (Hospitals, Clinics, Others), Diagnosis (Blood Test, Urine Test) Players and Region - Global Market Outlook to 2026

Tumor Lysis Syndrome Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Feb 2021 Edition 240 Pages 216 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Tumor Lysis Syndrome Market Scope
Tumor lysis syndrome (TLS) is a constellation of metabolic disturbances that occurs when a large number of cancer cells die within a short period, releasing their contents into the blood. TLS is most common in blood cancer patients including some leukemias and lymphomas. TLS increases the amounts of several substances in a patient's blood including potassium, uric acid, phosphate and calcium, which can cause a range of symptoms.

The Tumor Lysis Syndrome market study is segmented and major geographies with country level break-up.

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Tumor Lysis Syndrome market throughout the predicted period.

Johnson & Johnson Services, Inc. (United States), Amgen Inc. (United States), Genentech, Inc. (United States), Ionis Pharmaceuticals (United States), Sanofi S.A. (France), Menarini Group (Italy), Merck KGaA (Germany), Takeda Pharmaceutical Company Limited (Japan), Ironwood Pharmaceuticals, Inc. (United States), AstraZeneca plc (United Kingdom), Hikma Pharmaceuticals PLC (United Kingdom), Pfizer Inc. (United States), Lonza Group AG (Switzerland), Alexion Pharmaceuticals, Inc. (United States), Teva Pharmaceutical Industries Ltd. (Israel), AbbVie Inc. (United States) and Merck & Co., Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are F. Hoffmann-La Roche Ltd (Switzerland) and Mallinckrodt Pharmaceuticals (United Kingdom).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Tumor Lysis Syndrome market by Type, Application and Region.

On the basis of geography, the market of Tumor Lysis Syndrome has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).




Market Trend
  • Rapid Advancements in Medical Science
  • Increased Awareness about Cancer Treatments

Market Drivers
  • Increased Prevalence of Cancers among People
  • Rise in the Number of Diagnostic Centres
  • Increase in Healthcare Expenditure in Developing Countries such as India and China

Opportunities
  • Growth in the Healthcare Industry Worldwide
  • Growing Number of Regulatory Approvals

Restraints
  • Side Effects of the Tumor Lysis Syndrome Treatment

Challenges
  • Stringent Government Rules and Regulations


Key Target Audience
Tumor Lysis Syndrome Treatment Providers, Distributors, Emerging Companies, Research Professionals and End-users

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Treatment
  • Medications (allopurinol, rasburicase, sodium bicarbonate or acetazolamide, oral kinase inhibitors and B-cell lymphoma-2 protein inhibitors)
  • Kidney Dialysis

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online
  • Others

By End-user
  • Hospitals
  • Clinics
  • Others

By Diagnosis
  • Blood Test
  • Urine Test

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Cancers among People
      • 3.2.2. Rise in the Number of Diagnostic Centres
      • 3.2.3. Increase in Healthcare Expenditure in Developing Countries such as India and China
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Rapid Advancements in Medical Science
      • 3.4.2. Increased Awareness about Cancer Treatments
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Tumor Lysis Syndrome, by Treatment, Distribution Channel, End-user, Diagnosis and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Tumor Lysis Syndrome (Value)
      • 5.2.1. Global Tumor Lysis Syndrome by: Treatment (Value)
        • 5.2.1.1. Medications (allopurinol, rasburicase, sodium bicarbonate or acetazolamide, oral kinase inhibitors and B-cell lymphoma-2 protein inhibitors)
        • 5.2.1.2. Kidney Dialysis
      • 5.2.2. Global Tumor Lysis Syndrome by: Distribution Channel (Value)
        • 5.2.2.1. Hospital Pharmacies
        • 5.2.2.2. Retail Pharmacies
        • 5.2.2.3. Online
        • 5.2.2.4. Others
      • 5.2.3. Global Tumor Lysis Syndrome by: End-user (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clinics
        • 5.2.3.3. Others
      • 5.2.4. Global Tumor Lysis Syndrome by: Diagnosis (Value)
        • 5.2.4.1. Blood Test
        • 5.2.4.2. Urine Test
      • 5.2.5. Global Tumor Lysis Syndrome Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Tumor Lysis Syndrome: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Johnson & Johnson Services, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Amgen Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Genentech, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Ionis Pharmaceuticals (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sanofi S.A. (France)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Menarini Group (Italy)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Merck KGaA (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Takeda Pharmaceutical Company Limited (Japan)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Ironwood Pharmaceuticals, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. AstraZeneca plc (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Hikma Pharmaceuticals PLC (United Kingdom)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Pfizer Inc. (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Lonza Group AG (Switzerland)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Alexion Pharmaceuticals, Inc. (United States)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
      • 6.4.16. AbbVie Inc. (United States)
        • 6.4.16.1. Business Overview
        • 6.4.16.2. Products/Services Offerings
        • 6.4.16.3. Financial Analysis
        • 6.4.16.4. SWOT Analysis
      • 6.4.17. Merck & Co., Inc. (United States)
        • 6.4.17.1. Business Overview
        • 6.4.17.2. Products/Services Offerings
        • 6.4.17.3. Financial Analysis
        • 6.4.17.4. SWOT Analysis
  • 7. Global Tumor Lysis Syndrome Sale, by Treatment, Distribution Channel, End-user, Diagnosis and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Tumor Lysis Syndrome (Value)
      • 7.2.1. Global Tumor Lysis Syndrome by: Treatment (Value)
        • 7.2.1.1. Medications (allopurinol, rasburicase, sodium bicarbonate or acetazolamide, oral kinase inhibitors and B-cell lymphoma-2 protein inhibitors)
        • 7.2.1.2. Kidney Dialysis
      • 7.2.2. Global Tumor Lysis Syndrome by: Distribution Channel (Value)
        • 7.2.2.1. Hospital Pharmacies
        • 7.2.2.2. Retail Pharmacies
        • 7.2.2.3. Online
        • 7.2.2.4. Others
      • 7.2.3. Global Tumor Lysis Syndrome by: End-user (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clinics
        • 7.2.3.3. Others
      • 7.2.4. Global Tumor Lysis Syndrome by: Diagnosis (Value)
        • 7.2.4.1. Blood Test
        • 7.2.4.2. Urine Test
      • 7.2.5. Global Tumor Lysis Syndrome Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Tumor Lysis Syndrome: by Treatment(USD Million)
  • Table 2. Tumor Lysis Syndrome Medications (allopurinol, rasburicase, sodium bicarbonate or acetazolamide, oral kinase inhibitors and B-cell lymphoma-2 protein inhibitors) , by Region USD Million (2015-2020)
  • Table 3. Tumor Lysis Syndrome Kidney Dialysis , by Region USD Million (2015-2020)
  • Table 4. Tumor Lysis Syndrome: by Distribution Channel(USD Million)
  • Table 5. Tumor Lysis Syndrome Hospital Pharmacies , by Region USD Million (2015-2020)
  • Table 6. Tumor Lysis Syndrome Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 7. Tumor Lysis Syndrome Online , by Region USD Million (2015-2020)
  • Table 8. Tumor Lysis Syndrome Others , by Region USD Million (2015-2020)
  • Table 9. Tumor Lysis Syndrome: by End-user(USD Million)
  • Table 10. Tumor Lysis Syndrome Hospitals , by Region USD Million (2015-2020)
  • Table 11. Tumor Lysis Syndrome Clinics , by Region USD Million (2015-2020)
  • Table 12. Tumor Lysis Syndrome Others , by Region USD Million (2015-2020)
  • Table 13. Tumor Lysis Syndrome: by Diagnosis(USD Million)
  • Table 14. Tumor Lysis Syndrome Blood Test , by Region USD Million (2015-2020)
  • Table 15. Tumor Lysis Syndrome Urine Test , by Region USD Million (2015-2020)
  • Table 16. South America Tumor Lysis Syndrome, by Country USD Million (2015-2020)
  • Table 17. South America Tumor Lysis Syndrome, by Treatment USD Million (2015-2020)
  • Table 18. South America Tumor Lysis Syndrome, by Distribution Channel USD Million (2015-2020)
  • Table 19. South America Tumor Lysis Syndrome, by End-user USD Million (2015-2020)
  • Table 20. South America Tumor Lysis Syndrome, by Diagnosis USD Million (2015-2020)
  • Table 21. Brazil Tumor Lysis Syndrome, by Treatment USD Million (2015-2020)
  • Table 22. Brazil Tumor Lysis Syndrome, by Distribution Channel USD Million (2015-2020)
  • Table 23. Brazil Tumor Lysis Syndrome, by End-user USD Million (2015-2020)
  • Table 24. Brazil Tumor Lysis Syndrome, by Diagnosis USD Million (2015-2020)
  • Table 25. Argentina Tumor Lysis Syndrome, by Treatment USD Million (2015-2020)
  • Table 26. Argentina Tumor Lysis Syndrome, by Distribution Channel USD Million (2015-2020)
  • Table 27. Argentina Tumor Lysis Syndrome, by End-user USD Million (2015-2020)
  • Table 28. Argentina Tumor Lysis Syndrome, by Diagnosis USD Million (2015-2020)
  • Table 29. Rest of South America Tumor Lysis Syndrome, by Treatment USD Million (2015-2020)
  • Table 30. Rest of South America Tumor Lysis Syndrome, by Distribution Channel USD Million (2015-2020)
  • Table 31. Rest of South America Tumor Lysis Syndrome, by End-user USD Million (2015-2020)
  • Table 32. Rest of South America Tumor Lysis Syndrome, by Diagnosis USD Million (2015-2020)
  • Table 33. Asia Pacific Tumor Lysis Syndrome, by Country USD Million (2015-2020)
  • Table 34. Asia Pacific Tumor Lysis Syndrome, by Treatment USD Million (2015-2020)
  • Table 35. Asia Pacific Tumor Lysis Syndrome, by Distribution Channel USD Million (2015-2020)
  • Table 36. Asia Pacific Tumor Lysis Syndrome, by End-user USD Million (2015-2020)
  • Table 37. Asia Pacific Tumor Lysis Syndrome, by Diagnosis USD Million (2015-2020)
  • Table 38. China Tumor Lysis Syndrome, by Treatment USD Million (2015-2020)
  • Table 39. China Tumor Lysis Syndrome, by Distribution Channel USD Million (2015-2020)
  • Table 40. China Tumor Lysis Syndrome, by End-user USD Million (2015-2020)
  • Table 41. China Tumor Lysis Syndrome, by Diagnosis USD Million (2015-2020)
  • Table 42. Japan Tumor Lysis Syndrome, by Treatment USD Million (2015-2020)
  • Table 43. Japan Tumor Lysis Syndrome, by Distribution Channel USD Million (2015-2020)
  • Table 44. Japan Tumor Lysis Syndrome, by End-user USD Million (2015-2020)
  • Table 45. Japan Tumor Lysis Syndrome, by Diagnosis USD Million (2015-2020)
  • Table 46. India Tumor Lysis Syndrome, by Treatment USD Million (2015-2020)
  • Table 47. India Tumor Lysis Syndrome, by Distribution Channel USD Million (2015-2020)
  • Table 48. India Tumor Lysis Syndrome, by End-user USD Million (2015-2020)
  • Table 49. India Tumor Lysis Syndrome, by Diagnosis USD Million (2015-2020)
  • Table 50. South Korea Tumor Lysis Syndrome, by Treatment USD Million (2015-2020)
  • Table 51. South Korea Tumor Lysis Syndrome, by Distribution Channel USD Million (2015-2020)
  • Table 52. South Korea Tumor Lysis Syndrome, by End-user USD Million (2015-2020)
  • Table 53. South Korea Tumor Lysis Syndrome, by Diagnosis USD Million (2015-2020)
  • Table 54. Taiwan Tumor Lysis Syndrome, by Treatment USD Million (2015-2020)
  • Table 55. Taiwan Tumor Lysis Syndrome, by Distribution Channel USD Million (2015-2020)
  • Table 56. Taiwan Tumor Lysis Syndrome, by End-user USD Million (2015-2020)
  • Table 57. Taiwan Tumor Lysis Syndrome, by Diagnosis USD Million (2015-2020)
  • Table 58. Australia Tumor Lysis Syndrome, by Treatment USD Million (2015-2020)
  • Table 59. Australia Tumor Lysis Syndrome, by Distribution Channel USD Million (2015-2020)
  • Table 60. Australia Tumor Lysis Syndrome, by End-user USD Million (2015-2020)
  • Table 61. Australia Tumor Lysis Syndrome, by Diagnosis USD Million (2015-2020)
  • Table 62. Rest of Asia-Pacific Tumor Lysis Syndrome, by Treatment USD Million (2015-2020)
  • Table 63. Rest of Asia-Pacific Tumor Lysis Syndrome, by Distribution Channel USD Million (2015-2020)
  • Table 64. Rest of Asia-Pacific Tumor Lysis Syndrome, by End-user USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific Tumor Lysis Syndrome, by Diagnosis USD Million (2015-2020)
  • Table 66. Europe Tumor Lysis Syndrome, by Country USD Million (2015-2020)
  • Table 67. Europe Tumor Lysis Syndrome, by Treatment USD Million (2015-2020)
  • Table 68. Europe Tumor Lysis Syndrome, by Distribution Channel USD Million (2015-2020)
  • Table 69. Europe Tumor Lysis Syndrome, by End-user USD Million (2015-2020)
  • Table 70. Europe Tumor Lysis Syndrome, by Diagnosis USD Million (2015-2020)
  • Table 71. Germany Tumor Lysis Syndrome, by Treatment USD Million (2015-2020)
  • Table 72. Germany Tumor Lysis Syndrome, by Distribution Channel USD Million (2015-2020)
  • Table 73. Germany Tumor Lysis Syndrome, by End-user USD Million (2015-2020)
  • Table 74. Germany Tumor Lysis Syndrome, by Diagnosis USD Million (2015-2020)
  • Table 75. France Tumor Lysis Syndrome, by Treatment USD Million (2015-2020)
  • Table 76. France Tumor Lysis Syndrome, by Distribution Channel USD Million (2015-2020)
  • Table 77. France Tumor Lysis Syndrome, by End-user USD Million (2015-2020)
  • Table 78. France Tumor Lysis Syndrome, by Diagnosis USD Million (2015-2020)
  • Table 79. Italy Tumor Lysis Syndrome, by Treatment USD Million (2015-2020)
  • Table 80. Italy Tumor Lysis Syndrome, by Distribution Channel USD Million (2015-2020)
  • Table 81. Italy Tumor Lysis Syndrome, by End-user USD Million (2015-2020)
  • Table 82. Italy Tumor Lysis Syndrome, by Diagnosis USD Million (2015-2020)
  • Table 83. United Kingdom Tumor Lysis Syndrome, by Treatment USD Million (2015-2020)
  • Table 84. United Kingdom Tumor Lysis Syndrome, by Distribution Channel USD Million (2015-2020)
  • Table 85. United Kingdom Tumor Lysis Syndrome, by End-user USD Million (2015-2020)
  • Table 86. United Kingdom Tumor Lysis Syndrome, by Diagnosis USD Million (2015-2020)
  • Table 87. Netherlands Tumor Lysis Syndrome, by Treatment USD Million (2015-2020)
  • Table 88. Netherlands Tumor Lysis Syndrome, by Distribution Channel USD Million (2015-2020)
  • Table 89. Netherlands Tumor Lysis Syndrome, by End-user USD Million (2015-2020)
  • Table 90. Netherlands Tumor Lysis Syndrome, by Diagnosis USD Million (2015-2020)
  • Table 91. Rest of Europe Tumor Lysis Syndrome, by Treatment USD Million (2015-2020)
  • Table 92. Rest of Europe Tumor Lysis Syndrome, by Distribution Channel USD Million (2015-2020)
  • Table 93. Rest of Europe Tumor Lysis Syndrome, by End-user USD Million (2015-2020)
  • Table 94. Rest of Europe Tumor Lysis Syndrome, by Diagnosis USD Million (2015-2020)
  • Table 95. MEA Tumor Lysis Syndrome, by Country USD Million (2015-2020)
  • Table 96. MEA Tumor Lysis Syndrome, by Treatment USD Million (2015-2020)
  • Table 97. MEA Tumor Lysis Syndrome, by Distribution Channel USD Million (2015-2020)
  • Table 98. MEA Tumor Lysis Syndrome, by End-user USD Million (2015-2020)
  • Table 99. MEA Tumor Lysis Syndrome, by Diagnosis USD Million (2015-2020)
  • Table 100. Middle East Tumor Lysis Syndrome, by Treatment USD Million (2015-2020)
  • Table 101. Middle East Tumor Lysis Syndrome, by Distribution Channel USD Million (2015-2020)
  • Table 102. Middle East Tumor Lysis Syndrome, by End-user USD Million (2015-2020)
  • Table 103. Middle East Tumor Lysis Syndrome, by Diagnosis USD Million (2015-2020)
  • Table 104. Africa Tumor Lysis Syndrome, by Treatment USD Million (2015-2020)
  • Table 105. Africa Tumor Lysis Syndrome, by Distribution Channel USD Million (2015-2020)
  • Table 106. Africa Tumor Lysis Syndrome, by End-user USD Million (2015-2020)
  • Table 107. Africa Tumor Lysis Syndrome, by Diagnosis USD Million (2015-2020)
  • Table 108. North America Tumor Lysis Syndrome, by Country USD Million (2015-2020)
  • Table 109. North America Tumor Lysis Syndrome, by Treatment USD Million (2015-2020)
  • Table 110. North America Tumor Lysis Syndrome, by Distribution Channel USD Million (2015-2020)
  • Table 111. North America Tumor Lysis Syndrome, by End-user USD Million (2015-2020)
  • Table 112. North America Tumor Lysis Syndrome, by Diagnosis USD Million (2015-2020)
  • Table 113. United States Tumor Lysis Syndrome, by Treatment USD Million (2015-2020)
  • Table 114. United States Tumor Lysis Syndrome, by Distribution Channel USD Million (2015-2020)
  • Table 115. United States Tumor Lysis Syndrome, by End-user USD Million (2015-2020)
  • Table 116. United States Tumor Lysis Syndrome, by Diagnosis USD Million (2015-2020)
  • Table 117. Canada Tumor Lysis Syndrome, by Treatment USD Million (2015-2020)
  • Table 118. Canada Tumor Lysis Syndrome, by Distribution Channel USD Million (2015-2020)
  • Table 119. Canada Tumor Lysis Syndrome, by End-user USD Million (2015-2020)
  • Table 120. Canada Tumor Lysis Syndrome, by Diagnosis USD Million (2015-2020)
  • Table 121. Mexico Tumor Lysis Syndrome, by Treatment USD Million (2015-2020)
  • Table 122. Mexico Tumor Lysis Syndrome, by Distribution Channel USD Million (2015-2020)
  • Table 123. Mexico Tumor Lysis Syndrome, by End-user USD Million (2015-2020)
  • Table 124. Mexico Tumor Lysis Syndrome, by Diagnosis USD Million (2015-2020)
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Tumor Lysis Syndrome: by Treatment(USD Million)
  • Table 143. Tumor Lysis Syndrome Medications (allopurinol, rasburicase, sodium bicarbonate or acetazolamide, oral kinase inhibitors and B-cell lymphoma-2 protein inhibitors) , by Region USD Million (2021-2026)
  • Table 144. Tumor Lysis Syndrome Kidney Dialysis , by Region USD Million (2021-2026)
  • Table 145. Tumor Lysis Syndrome: by Distribution Channel(USD Million)
  • Table 146. Tumor Lysis Syndrome Hospital Pharmacies , by Region USD Million (2021-2026)
  • Table 147. Tumor Lysis Syndrome Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 148. Tumor Lysis Syndrome Online , by Region USD Million (2021-2026)
  • Table 149. Tumor Lysis Syndrome Others , by Region USD Million (2021-2026)
  • Table 150. Tumor Lysis Syndrome: by End-user(USD Million)
  • Table 151. Tumor Lysis Syndrome Hospitals , by Region USD Million (2021-2026)
  • Table 152. Tumor Lysis Syndrome Clinics , by Region USD Million (2021-2026)
  • Table 153. Tumor Lysis Syndrome Others , by Region USD Million (2021-2026)
  • Table 154. Tumor Lysis Syndrome: by Diagnosis(USD Million)
  • Table 155. Tumor Lysis Syndrome Blood Test , by Region USD Million (2021-2026)
  • Table 156. Tumor Lysis Syndrome Urine Test , by Region USD Million (2021-2026)
  • Table 157. South America Tumor Lysis Syndrome, by Country USD Million (2021-2026)
  • Table 158. South America Tumor Lysis Syndrome, by Treatment USD Million (2021-2026)
  • Table 159. South America Tumor Lysis Syndrome, by Distribution Channel USD Million (2021-2026)
  • Table 160. South America Tumor Lysis Syndrome, by End-user USD Million (2021-2026)
  • Table 161. South America Tumor Lysis Syndrome, by Diagnosis USD Million (2021-2026)
  • Table 162. Brazil Tumor Lysis Syndrome, by Treatment USD Million (2021-2026)
  • Table 163. Brazil Tumor Lysis Syndrome, by Distribution Channel USD Million (2021-2026)
  • Table 164. Brazil Tumor Lysis Syndrome, by End-user USD Million (2021-2026)
  • Table 165. Brazil Tumor Lysis Syndrome, by Diagnosis USD Million (2021-2026)
  • Table 166. Argentina Tumor Lysis Syndrome, by Treatment USD Million (2021-2026)
  • Table 167. Argentina Tumor Lysis Syndrome, by Distribution Channel USD Million (2021-2026)
  • Table 168. Argentina Tumor Lysis Syndrome, by End-user USD Million (2021-2026)
  • Table 169. Argentina Tumor Lysis Syndrome, by Diagnosis USD Million (2021-2026)
  • Table 170. Rest of South America Tumor Lysis Syndrome, by Treatment USD Million (2021-2026)
  • Table 171. Rest of South America Tumor Lysis Syndrome, by Distribution Channel USD Million (2021-2026)
  • Table 172. Rest of South America Tumor Lysis Syndrome, by End-user USD Million (2021-2026)
  • Table 173. Rest of South America Tumor Lysis Syndrome, by Diagnosis USD Million (2021-2026)
  • Table 174. Asia Pacific Tumor Lysis Syndrome, by Country USD Million (2021-2026)
  • Table 175. Asia Pacific Tumor Lysis Syndrome, by Treatment USD Million (2021-2026)
  • Table 176. Asia Pacific Tumor Lysis Syndrome, by Distribution Channel USD Million (2021-2026)
  • Table 177. Asia Pacific Tumor Lysis Syndrome, by End-user USD Million (2021-2026)
  • Table 178. Asia Pacific Tumor Lysis Syndrome, by Diagnosis USD Million (2021-2026)
  • Table 179. China Tumor Lysis Syndrome, by Treatment USD Million (2021-2026)
  • Table 180. China Tumor Lysis Syndrome, by Distribution Channel USD Million (2021-2026)
  • Table 181. China Tumor Lysis Syndrome, by End-user USD Million (2021-2026)
  • Table 182. China Tumor Lysis Syndrome, by Diagnosis USD Million (2021-2026)
  • Table 183. Japan Tumor Lysis Syndrome, by Treatment USD Million (2021-2026)
  • Table 184. Japan Tumor Lysis Syndrome, by Distribution Channel USD Million (2021-2026)
  • Table 185. Japan Tumor Lysis Syndrome, by End-user USD Million (2021-2026)
  • Table 186. Japan Tumor Lysis Syndrome, by Diagnosis USD Million (2021-2026)
  • Table 187. India Tumor Lysis Syndrome, by Treatment USD Million (2021-2026)
  • Table 188. India Tumor Lysis Syndrome, by Distribution Channel USD Million (2021-2026)
  • Table 189. India Tumor Lysis Syndrome, by End-user USD Million (2021-2026)
  • Table 190. India Tumor Lysis Syndrome, by Diagnosis USD Million (2021-2026)
  • Table 191. South Korea Tumor Lysis Syndrome, by Treatment USD Million (2021-2026)
  • Table 192. South Korea Tumor Lysis Syndrome, by Distribution Channel USD Million (2021-2026)
  • Table 193. South Korea Tumor Lysis Syndrome, by End-user USD Million (2021-2026)
  • Table 194. South Korea Tumor Lysis Syndrome, by Diagnosis USD Million (2021-2026)
  • Table 195. Taiwan Tumor Lysis Syndrome, by Treatment USD Million (2021-2026)
  • Table 196. Taiwan Tumor Lysis Syndrome, by Distribution Channel USD Million (2021-2026)
  • Table 197. Taiwan Tumor Lysis Syndrome, by End-user USD Million (2021-2026)
  • Table 198. Taiwan Tumor Lysis Syndrome, by Diagnosis USD Million (2021-2026)
  • Table 199. Australia Tumor Lysis Syndrome, by Treatment USD Million (2021-2026)
  • Table 200. Australia Tumor Lysis Syndrome, by Distribution Channel USD Million (2021-2026)
  • Table 201. Australia Tumor Lysis Syndrome, by End-user USD Million (2021-2026)
  • Table 202. Australia Tumor Lysis Syndrome, by Diagnosis USD Million (2021-2026)
  • Table 203. Rest of Asia-Pacific Tumor Lysis Syndrome, by Treatment USD Million (2021-2026)
  • Table 204. Rest of Asia-Pacific Tumor Lysis Syndrome, by Distribution Channel USD Million (2021-2026)
  • Table 205. Rest of Asia-Pacific Tumor Lysis Syndrome, by End-user USD Million (2021-2026)
  • Table 206. Rest of Asia-Pacific Tumor Lysis Syndrome, by Diagnosis USD Million (2021-2026)
  • Table 207. Europe Tumor Lysis Syndrome, by Country USD Million (2021-2026)
  • Table 208. Europe Tumor Lysis Syndrome, by Treatment USD Million (2021-2026)
  • Table 209. Europe Tumor Lysis Syndrome, by Distribution Channel USD Million (2021-2026)
  • Table 210. Europe Tumor Lysis Syndrome, by End-user USD Million (2021-2026)
  • Table 211. Europe Tumor Lysis Syndrome, by Diagnosis USD Million (2021-2026)
  • Table 212. Germany Tumor Lysis Syndrome, by Treatment USD Million (2021-2026)
  • Table 213. Germany Tumor Lysis Syndrome, by Distribution Channel USD Million (2021-2026)
  • Table 214. Germany Tumor Lysis Syndrome, by End-user USD Million (2021-2026)
  • Table 215. Germany Tumor Lysis Syndrome, by Diagnosis USD Million (2021-2026)
  • Table 216. France Tumor Lysis Syndrome, by Treatment USD Million (2021-2026)
  • Table 217. France Tumor Lysis Syndrome, by Distribution Channel USD Million (2021-2026)
  • Table 218. France Tumor Lysis Syndrome, by End-user USD Million (2021-2026)
  • Table 219. France Tumor Lysis Syndrome, by Diagnosis USD Million (2021-2026)
  • Table 220. Italy Tumor Lysis Syndrome, by Treatment USD Million (2021-2026)
  • Table 221. Italy Tumor Lysis Syndrome, by Distribution Channel USD Million (2021-2026)
  • Table 222. Italy Tumor Lysis Syndrome, by End-user USD Million (2021-2026)
  • Table 223. Italy Tumor Lysis Syndrome, by Diagnosis USD Million (2021-2026)
  • Table 224. United Kingdom Tumor Lysis Syndrome, by Treatment USD Million (2021-2026)
  • Table 225. United Kingdom Tumor Lysis Syndrome, by Distribution Channel USD Million (2021-2026)
  • Table 226. United Kingdom Tumor Lysis Syndrome, by End-user USD Million (2021-2026)
  • Table 227. United Kingdom Tumor Lysis Syndrome, by Diagnosis USD Million (2021-2026)
  • Table 228. Netherlands Tumor Lysis Syndrome, by Treatment USD Million (2021-2026)
  • Table 229. Netherlands Tumor Lysis Syndrome, by Distribution Channel USD Million (2021-2026)
  • Table 230. Netherlands Tumor Lysis Syndrome, by End-user USD Million (2021-2026)
  • Table 231. Netherlands Tumor Lysis Syndrome, by Diagnosis USD Million (2021-2026)
  • Table 232. Rest of Europe Tumor Lysis Syndrome, by Treatment USD Million (2021-2026)
  • Table 233. Rest of Europe Tumor Lysis Syndrome, by Distribution Channel USD Million (2021-2026)
  • Table 234. Rest of Europe Tumor Lysis Syndrome, by End-user USD Million (2021-2026)
  • Table 235. Rest of Europe Tumor Lysis Syndrome, by Diagnosis USD Million (2021-2026)
  • Table 236. MEA Tumor Lysis Syndrome, by Country USD Million (2021-2026)
  • Table 237. MEA Tumor Lysis Syndrome, by Treatment USD Million (2021-2026)
  • Table 238. MEA Tumor Lysis Syndrome, by Distribution Channel USD Million (2021-2026)
  • Table 239. MEA Tumor Lysis Syndrome, by End-user USD Million (2021-2026)
  • Table 240. MEA Tumor Lysis Syndrome, by Diagnosis USD Million (2021-2026)
  • Table 241. Middle East Tumor Lysis Syndrome, by Treatment USD Million (2021-2026)
  • Table 242. Middle East Tumor Lysis Syndrome, by Distribution Channel USD Million (2021-2026)
  • Table 243. Middle East Tumor Lysis Syndrome, by End-user USD Million (2021-2026)
  • Table 244. Middle East Tumor Lysis Syndrome, by Diagnosis USD Million (2021-2026)
  • Table 245. Africa Tumor Lysis Syndrome, by Treatment USD Million (2021-2026)
  • Table 246. Africa Tumor Lysis Syndrome, by Distribution Channel USD Million (2021-2026)
  • Table 247. Africa Tumor Lysis Syndrome, by End-user USD Million (2021-2026)
  • Table 248. Africa Tumor Lysis Syndrome, by Diagnosis USD Million (2021-2026)
  • Table 249. North America Tumor Lysis Syndrome, by Country USD Million (2021-2026)
  • Table 250. North America Tumor Lysis Syndrome, by Treatment USD Million (2021-2026)
  • Table 251. North America Tumor Lysis Syndrome, by Distribution Channel USD Million (2021-2026)
  • Table 252. North America Tumor Lysis Syndrome, by End-user USD Million (2021-2026)
  • Table 253. North America Tumor Lysis Syndrome, by Diagnosis USD Million (2021-2026)
  • Table 254. United States Tumor Lysis Syndrome, by Treatment USD Million (2021-2026)
  • Table 255. United States Tumor Lysis Syndrome, by Distribution Channel USD Million (2021-2026)
  • Table 256. United States Tumor Lysis Syndrome, by End-user USD Million (2021-2026)
  • Table 257. United States Tumor Lysis Syndrome, by Diagnosis USD Million (2021-2026)
  • Table 258. Canada Tumor Lysis Syndrome, by Treatment USD Million (2021-2026)
  • Table 259. Canada Tumor Lysis Syndrome, by Distribution Channel USD Million (2021-2026)
  • Table 260. Canada Tumor Lysis Syndrome, by End-user USD Million (2021-2026)
  • Table 261. Canada Tumor Lysis Syndrome, by Diagnosis USD Million (2021-2026)
  • Table 262. Mexico Tumor Lysis Syndrome, by Treatment USD Million (2021-2026)
  • Table 263. Mexico Tumor Lysis Syndrome, by Distribution Channel USD Million (2021-2026)
  • Table 264. Mexico Tumor Lysis Syndrome, by End-user USD Million (2021-2026)
  • Table 265. Mexico Tumor Lysis Syndrome, by Diagnosis USD Million (2021-2026)
  • Table 266. Research Programs/Design for This Report
  • Table 267. Key Data Information from Secondary Sources
  • Table 268. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Tumor Lysis Syndrome: by Treatment USD Million (2015-2020)
  • Figure 5. Global Tumor Lysis Syndrome: by Distribution Channel USD Million (2015-2020)
  • Figure 6. Global Tumor Lysis Syndrome: by End-user USD Million (2015-2020)
  • Figure 7. Global Tumor Lysis Syndrome: by Diagnosis USD Million (2015-2020)
  • Figure 8. South America Tumor Lysis Syndrome Share (%), by Country
  • Figure 9. Asia Pacific Tumor Lysis Syndrome Share (%), by Country
  • Figure 10. Europe Tumor Lysis Syndrome Share (%), by Country
  • Figure 11. MEA Tumor Lysis Syndrome Share (%), by Country
  • Figure 12. North America Tumor Lysis Syndrome Share (%), by Country
  • Figure 13. Global Tumor Lysis Syndrome share by Players 2020 (%)
  • Figure 14. Global Tumor Lysis Syndrome share by Players (Top 3) 2020(%)
  • Figure 15. Global Tumor Lysis Syndrome share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Johnson & Johnson Services, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Johnson & Johnson Services, Inc. (United States) Revenue: by Geography 2020
  • Figure 19. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Amgen Inc. (United States) Revenue: by Geography 2020
  • Figure 21. Genentech, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Genentech, Inc. (United States) Revenue: by Geography 2020
  • Figure 23. Ionis Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 24. Ionis Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 25. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 26. Sanofi S.A. (France) Revenue: by Geography 2020
  • Figure 27. Menarini Group (Italy) Revenue, Net Income and Gross profit
  • Figure 28. Menarini Group (Italy) Revenue: by Geography 2020
  • Figure 29. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 30. Merck KGaA (Germany) Revenue: by Geography 2020
  • Figure 31. Takeda Pharmaceutical Company Limited (Japan) Revenue, Net Income and Gross profit
  • Figure 32. Takeda Pharmaceutical Company Limited (Japan) Revenue: by Geography 2020
  • Figure 33. Ironwood Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Ironwood Pharmaceuticals, Inc. (United States) Revenue: by Geography 2020
  • Figure 35. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 36. AstraZeneca plc (United Kingdom) Revenue: by Geography 2020
  • Figure 37. Hikma Pharmaceuticals PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 38. Hikma Pharmaceuticals PLC (United Kingdom) Revenue: by Geography 2020
  • Figure 39. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 40. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 41. Lonza Group AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 42. Lonza Group AG (Switzerland) Revenue: by Geography 2020
  • Figure 43. Alexion Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 44. Alexion Pharmaceuticals, Inc. (United States) Revenue: by Geography 2020
  • Figure 45. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 46. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2020
  • Figure 47. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 48. AbbVie Inc. (United States) Revenue: by Geography 2020
  • Figure 49. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 50. Merck & Co., Inc. (United States) Revenue: by Geography 2020
  • Figure 51. Global Tumor Lysis Syndrome: by Treatment USD Million (2021-2026)
  • Figure 52. Global Tumor Lysis Syndrome: by Distribution Channel USD Million (2021-2026)
  • Figure 53. Global Tumor Lysis Syndrome: by End-user USD Million (2021-2026)
  • Figure 54. Global Tumor Lysis Syndrome: by Diagnosis USD Million (2021-2026)
  • Figure 55. South America Tumor Lysis Syndrome Share (%), by Country
  • Figure 56. Asia Pacific Tumor Lysis Syndrome Share (%), by Country
  • Figure 57. Europe Tumor Lysis Syndrome Share (%), by Country
  • Figure 58. MEA Tumor Lysis Syndrome Share (%), by Country
  • Figure 59. North America Tumor Lysis Syndrome Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Johnson & Johnson Services, Inc. (United States)
  • Amgen Inc. (United States)
  • Genentech, Inc. (United States)
  • Ionis Pharmaceuticals (United States)
  • Sanofi S.A. (France)
  • Menarini Group (Italy)
  • Merck KGaA (Germany)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Ironwood Pharmaceuticals, Inc. (United States)
  • AstraZeneca plc (United Kingdom)
  • Hikma Pharmaceuticals PLC (United Kingdom)
  • Pfizer Inc. (United States)
  • Lonza Group AG (Switzerland)
  • Alexion Pharmaceuticals, Inc. (United States)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • AbbVie Inc. (United States)
  • Merck & Co., Inc. (United States)
Additional players considered in the study are as follows:
F. Hoffmann-La Roche Ltd (Switzerland) , Mallinckrodt Pharmaceuticals (United Kingdom)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation